Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 1/20 | 0.44 |
| ▸ | PRKCI | P41743 | 4/20 | 0.40 |
| ▸ | AXL | P30530 | 2/20 | 0.37 |
| ▸ | AHR | P35869 | 2/20 | 0.34 |
| ▸ | EGFR | P00533 | 1/20 | 0.34 |
| ▸ | CCR8 | P51685 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.32 |
| ▸ | PARP1 | P09874 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | ZAP70 | P43403 | 1/20 | 0.30 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.30 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.30 |
| ▸ | DRD2 | P14416 | 1/20 | 0.30 |
| ▸ | DRD4 | P21917 | 1/20 | 0.30 |
| ▸ | DRD3 | P35462 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31279052 | 1.00 | DYRK1A (0.44) | DYRK1APRKCIAXLAHREGFR | |
| SCHEMBL23912514 | 0.85 | PRKCI (0.40) | DYRK1APRKCIAXLAHREGFR | |
| SCHEMBL12491412 | 0.80 | DYRK1A (0.47) | DYRK1APRKCIAXLAHRCCR8 | |
| SCHEMBL2211568 | 0.80 | PRKCI (0.42) | DYRK1APRKCIAXLAHRCCR8 | |
| SCHEMBL31275318 | 0.80 | PRKCI (0.42) | DYRK1APRKCIAXLAHRCCR8 | |
| SCHEMBL31452765 | 0.77 | DYRK1A (0.44) | DYRK1APRKCIAXLAHRCCR8 | |
| SCHEMBL9942629 | 0.77 | DYRK1A (0.44) | DYRK1APRKCIAXLAHRCCR8 | |
| SCHEMBL2674588 | 0.77 | PIK3C3 (0.41) | PRKCIAXLAHRPARP1MAPK1 | |
| SCHEMBL2628869 | 0.77 | AXL (0.53) | DYRK1APRKCIAXLAHRCCR8 | |
| SCHEMBL1763343 | 0.77 | DYRK1A (0.44) | DYRK1APRKCIAXLAHRCCR8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 265 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3814360-B1 | HETEROARYL COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE | PTC THERAPEUTICS INC (US) | 2024-10-02 | — | — | EP | disclosed |
| US-11685746-B2 | Heteroaryl compounds for treating Huntington's disease | PTC THERAPEUTICS, INC. (US) | 2023-06-27 | — | — | US | disclosed |
| US-11685746-B2 | Heteroaryl compounds for treating Huntington's disease | PTC THERAPEUTICS, INC. (US) | 2023-06-27 | — | — | US | disclosed |
| US-11685746-B2 | Heteroaryl compounds for treating Huntington's disease | PTC THERAPEUTICS, INC. (US) | 2023-06-27 | — | — | US | disclosed |
| US-20220213062-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION | PMV PHARMACEUTICALS, INC. | 2022-07-07 | — | — | US | disclosed |
| US-11369624-B2 | Salts of prodrugs of piperazine and substituted piperidine antiviral agents | VIIV HEALTHCARE UK (NO. 4) LIMITED | 2022-06-28 | — | — | US | disclosed |
| US-11369624-B2 | Salts of prodrugs of piperazine and substituted piperidine antiviral agents | VIIV HEALTHCARE UK (NO. 4) LIMITED | 2022-06-28 | — | — | US | disclosed |
| EP-4008328-A1 | PRIMARY CARBOXAMIDES AS BTK INHIBITORS | AbbVie Inc. (US) | 2022-06-08 | — | — | EP | disclosed |
| EP-4008328-A1 | PRIMARY CARBOXAMIDES AS BTK INHIBITORS | AbbVie Inc. (US) | 2022-06-08 | — | — | EP | disclosed |
| US-11339141-B2 | Methods and compounds for restoring mutant p53 function | PMV PHARMACEUTICALS, INC. (US) | 2022-05-24 | — | — | US | disclosed |
| WO-2004014380-A1 | COMPOSITION AND ANTIVIRAL ACTIVITY OF SUBSTITUTED AZAINDOLEOXOACETIC PIPERAZINE DERIVATIVES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-02-19 | — | — | WO | disclosed |
| US-20040023982-A1 | Antiviral azaindole derivatives | VIIV HEALTHCARE UK (NO. 5) LIMITED (GB) | 2004-02-05 | — | — | US | disclosed |
| EP-1363705-A1 | COMPOSITION AND ANTIVIRAL ACTIVITY OF SUBSTITUTED AZAINDOLEOXOACETIC PIPERAZINE DERIVATIVES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-11-26 | — | — | EP | disclosed |
| US-20030207910-A1 | Treatment of HIV and AIDS | VIIV HEALTHCARE UK (NO. 4) LIMITED (GB) | 2003-11-06 | — | — | US | disclosed |
| US-6632819-B1 | HIV and AIDS | BRISTOL-MYERS SQUIBB COMPANY | 2003-10-14 | — | — | US | disclosed |
| US-20030181463-A1 | Antiviral azaindole derivatives | VIIV HEALTHCARE UK (NO. 5) LIMITED (GB) | 2003-09-25 | — | — | US | disclosed |
| US-20030069266-A1 | Aids therapy | VIIV HEALTHCARE UK (NO. 4) LIMITED (GB) | 2003-04-10 | — | — | US | disclosed |
| US-6476034-B2 | AIDS THERAPY | BRISTOL-MYERS SQUIBB COMPANY | 2002-11-05 | — | — | US | disclosed |
| US-20020119982-A1 | Antiviral azaindole derivatives | VIIV HEALTHCARE UK (NO. 5) LIMITED (GB) | 2002-08-29 | — | — | US | disclosed |
| WO-2002062423-A1 | COMPOSITION AND ANTIVIRAL ACTIVITY OF SUBSTITUTED AZAINDOLEOXOACETIC PIPERAZINE DERIVATIVES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2002-08-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020119982-A1 | Antiviral azaindole derivatives | ZC3HAV1, MAVS, AZI2 | DYRK1A 3956/4885PRKCI 3590/4885AXL 4547/4885 |
| US-11339141-B2 | Methods and compounds for restoring mutant p53 function | TP53, TP53BP1, KRAS | DYRK1A 3489/4885PRKCI 259/4885AXL 4483/4885 |
| US-20220213062-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION | TP53, TP53BP1, KRAS | DYRK1A 3489/4885PRKCI 259/4885AXL 4483/4885 |
| US-20030069266-A1 | Aids therapy | ENTPD5, CCR5, ITPA | DYRK1A 4700/4885PRKCI 3395/4885AXL 3618/4885 |
| US-11685746-B2 | Heteroaryl compounds for treating Huntington's disease | HTT, HYPK, HDAC6 | DYRK1A 3566/4885PRKCI 4354/4885AXL 4798/4885 |
| US-11369624-B2 | Salts of prodrugs of piperazine and substituted piperidine antiviral agents | CCR5, ZC3HAV1L, CCRL2 | DYRK1A 3912/4885PRKCI 1446/4885AXL 4709/4885 |
| US-20040023982-A1 | Antiviral azaindole derivatives | ZC3HAV1, MAVS, EIF2AK2 | DYRK1A 3932/4885PRKCI 3421/4885AXL 4545/4885 |
| US-20030207910-A1 | Treatment of HIV and AIDS | CD4, CCR5, IDO1 | DYRK1A 4677/4885PRKCI 2931/4885AXL 3694/4885 |
| US-20030181463-A1 | Antiviral azaindole derivatives | ZC3HAV1, MAVS, AZI2 | DYRK1A 3956/4885PRKCI 3590/4885AXL 4547/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.